Q3 FY2026
Filed Nov 10, 2026Scholar Rock reports Q3 2026 net loss of $107.2 million as first ISEMBYLD product revenue of $570 thousand is recorded
The U.S. launch of ISEMBYLD has started and the company reports early demand and a $205 million PRV sale agreement, but product revenue is very small, the quarterly and nine-month net loss widened, and stockholders' equity fell from $245,488 thousand at December 31, 2025 to $168,676 thousand at September 30, 2026.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenue, net, Q3 2026 (Three Months Ended September 30, 2026)GAAP | $570K | – | – |
| Cost of revenue, Q3 2026GAAP | $8K | – | – |
| Research and development expense, Q3 2026GAAP | $54.13M | – | – |
| Selling, general and administrative expense, Q3 2026GAAP | $52.49M | – | – |
| Total operating expenses, Q3 2026GAAP | $106.6M | – | – |
| Loss from operations, Q3 2026GAAP | −$106.1M | – | – |
| Other income (expense), net, Q3 2026GAAP | −$1.18M | – | – |
| Net loss, Q3 2026GAAP | −$107.2M | – | – |
| Net loss per share, basic and diluted, Q3 2026GAAP | $(0.81) | – | – |
| Stock-based compensation included in net loss, Q3 2026GAAP | $17.9M | – | – |
| Stock-based compensation included in research and development expense, Q3 2026GAAP | $6.4M | – | – |
| Stock-based compensation included in selling, general and administrative expense, Q3 2026GAAP | $11.5M | – | – |
| Product revenue, net, nine months 2026 (Nine Months Ended September 30, 2026)GAAP | $570K | – | – |
| Cost of revenue, nine months 2026GAAP | $8K | – | – |
| Research and development expense, nine months 2026GAAP | $164.2M | – | – |
| Selling, general and administrative expense, nine months 2026GAAP | $153.4M | – | – |
| Total operating expenses, nine months 2026GAAP | $317.5M | – | – |
| Loss from operations, nine months 2026GAAP | −$317.0M | – | – |
| Other income (expense), net, nine months 2026GAAP | −$5.67M | – | – |
| Net loss, nine months 2026GAAP | −$322.6M | – | – |
| Net loss per share, basic and diluted, nine months 2026GAAP | $(2.48) | – | – |
| Cash, cash equivalents and marketable securities, September 30, 2026GAAP | $413.6M | – | – |
| Total assets, September 30, 2026GAAP | $446.0M | – | – |
| Total liabilities, September 30, 2026GAAP | $277.3M | – | – |
| Total stockholders' equity, September 30, 2026GAAP | $168.7M | – | – |
Capital returns
- The filing reports no share repurchases and no dividends for the quarter or the nine months.
- Equity financing is not described in the filing. Weighted average common shares outstanding rose from 113,729,850 to 132,372,289 for the quarter, a figure the filing prints but which is excluded from key metrics as a share count.
- The company states that the Priority Review Voucher sale for $205 million will provide non-dilutive capital to the balance sheet once closed.
What drove it
- ISEMBYLD was approved by the FDA on September 11, 2026 and shipped to the specialty network within one week of approval, and the company recorded $570 thousand of net product revenue for the quarter.
- The company states that cost of revenue was immaterial for the quarter and that, prior to FDA approval, product costs were expensed as research and development expense.
- The company states that a J-code application for an ISEMBYLD-specific J-code was submitted to CMS in September, with the J-code effective April 1, 2027.
- The company states that initial patients were infused in October 2026 and that it has an alternate fill-finish facility in place for the EMA resubmission, which it describes as the same site that supported the FDA approval.
- Research and development expense rose from $50,486 thousand to $54,128 thousand for the quarter, and from $161,565 thousand to $164,176 thousand for the nine months. The filing does not state a cause for the change.
- Selling, general and administrative expense was $52,495 thousand for the quarter, against $53,064 thousand a year earlier, and $153,364 thousand for the nine months, against $131,184 thousand a year earlier. The filing does not state a cause for the nine-month change.
Concerns
- Net loss widened to $(107,239) thousand from $(102,220) thousand for the quarter, and to $(322,645) thousand from $(286,974) thousand for the nine months.
- Product revenue of $570 thousand in the quarter is small against total operating expenses of $106,631 thousand for the same quarter.
- Total stockholders' equity fell from $245,488 thousand at December 31, 2025 to $168,676 thousand at September 30, 2026, while total liabilities rose from $158,784 thousand to $277,296 thousand.
- Long-term liabilities increased from $103,365 thousand to $197,172 thousand between the two balance sheet dates. The filing does not explain this change.
- The forward-looking statements section lists dependence on third parties for commercial supply of ISEMBYLD, the need for additional capital on acceptable terms, and whether early demand translates into sustained patient treatment and product revenue.
- The PRV sale has not closed. Its closing depends on customary conditions, including expiration of the HSR waiting period.
What to watch
- Closing of the $205 million PRV sale and receipt of the cash, subject to the HSR waiting period.
- Quarterly ISEMBYLD product revenue and whether early patient and physician demand converts into sustained treatment, as the company frames it.
- Timing of the ISEMBYLD-specific J-code effective date of April 1, 2027.
- CHMP opinion on the resubmitted apitegromab MAA, expected in the first half of 2027.
- PMDA review of the apitegromab JNDA under priority review, which the company says typically targets approximately nine months.
- SRK-439 Phase 1 topline data, expected by year end 2026, with data sharing planned for early 2027.
- Operating expense trend, particularly selling, general and administrative expense as the U.S. launch expands.
- Regulatory engagement on the development path for subcutaneous apitegromab.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $413,599 thousand at September 30, 2026, compared with $367,563 thousand at December 31, 2025.
- Total assets were $445,972 thousand at September 30, 2026, compared with $404,272 thousand at December 31, 2025.
- Current liabilities were $80,124 thousand at September 30, 2026, compared with $55,419 thousand at December 31, 2025.
- Long-term liabilities were $197,172 thousand at September 30, 2026, compared with $103,365 thousand at December 31, 2025.
- Total liabilities were $277,296 thousand at September 30, 2026, compared with $158,784 thousand at December 31, 2025.
- Total stockholders' equity was $168,676 thousand at September 30, 2026, compared with $245,488 thousand at December 31, 2025.
- The filing does not print a cash flow statement, operating cash flow or free cash flow for the period.
- The filing states that the PRV sale for $205 million is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and that cash will be received upon closing.
Analysis
Scholar Rock reports its first quarter of ISEMBYLD sales. Net product revenue was $570 thousand for the quarter ended September 30, 2026, with no revenue in the comparable quarter of 2025. The company states that cost of revenue was immaterial because product costs were expensed as research and development before FDA approval on September 11, 2026. Revenue is therefore very small relative to the cost base, and the filing does not provide a unit, patient or prescription figure to size the launch further.
The loss picture widened. Total operating expenses were $106,631 thousand for the quarter, against $103,550 thousand a year earlier, and the net loss was $(107,239) thousand against $(102,220) thousand. Research and development expense was $54,128 thousand against $50,486 thousand, and selling, general and administrative expense was $52,495 thousand against $53,064 thousand. For the nine months, selling, general and administrative expense was $153,364 thousand against $131,184 thousand, and the nine-month net loss was $(322,645) thousand against $(286,974) thousand. The filing does not give a cause for these movements. Stock-based compensation within net loss was $17.9 million against $18.3 million, with the R&D and SG&A components shown separately in the release.
The balance sheet shows cash, cash equivalents and marketable securities of $413,599 thousand at September 30, 2026, up from $367,563 thousand at December 31, 2025. Over the same interval total liabilities rose from $158,784 thousand to $277,296 thousand, led by long-term liabilities, which moved from $103,365 thousand to $197,172 thousand. Total stockholders' equity fell from $245,488 thousand to $168,676 thousand. The filing does not include a cash flow statement, so operating cash burn for the period cannot be read from these documents.
After quarter-end, the company entered into a definitive agreement to sell its Priority Review Voucher for $205 million. Closing is subject to customary conditions, including expiration of the Hart-Scott-Rodino waiting period, and the company describes the cash as non-dilutive capital. Regulatory milestones are set out with timing: a CHMP opinion on the resubmitted EU MAA is expected in the first half of 2027, the Japanese application is under priority review, and SRK-439 topline data are expected by year end 2026.
The filing provides no guidance for revenue, operating expenses or margins, so there is no prior outlook to compare against. The key points for a reader are the early but very small launch revenue, the widened net loss, the drop in equity, and the pending PRV proceeds, which the company has not yet received.
Management, verbatim
The third quarter was a defining period for Scholar Rock, marked by the FDA approval and U.S. launch of ISEMBYLD, the world's first and only muscle-targeted therapy for children and adults living with SMA.
David L. Hallal, Chairman and Chief Executive Officer
We are very encouraged by the early ISEMBYLD launch dynamics in the U.S., where the breadth of early demand across SMA treatment centers, physicians, and patients reinforces the significant unmet need in the SMA community.
David L. Hallal, Chairman and Chief Executive Officer
Not in the filing
stated, not guessed- Prior-year and prior-quarter comparatives for the ISEMBYLD product revenue line in the second quarter of 2026, because the filing does not print a June 30, 2026 balance sheet or a second-quarter income statement.
- Prior-quarter (June 30, 2026) cash, cash equivalents and marketable securities, total assets, total liabilities and stockholders' equity, because the filing prints only September 30, 2026 and December 31, 2025 balance sheets.
- Cash flow statement, operating cash flow and free cash flow for the quarter and the nine months.
- Year-over-year change percentages for any line item, because the filing prints dollar amounts but no percentage changes.
- Forward guidance for revenue, gross margin, operating expenses or tax rate, because the filing provides none.
- Segment or geographic revenue breakdown, because the filing reports a single product revenue line.
- Non-GAAP reconciliation or non-GAAP operating metrics, because the filing does not print them.
- Explanation from the company for the nine-month increase in selling, general and administrative expense and for the increase in long-term liabilities.
- Dollar figure for the PRV sale proceeds received to date, since the cash is to be received upon closing and the closing has not occurred.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.